Chevrier 1999.

Methods	Study design: parallel‐group RCT Country: Canada Number randomized: Total: all laser treatments = 85, trabeculoplasty = 51 Per group: all laser treatments, brimonidine = 43, apraclonidine = 42; trabeculoplasty, brimonidine = 27, apraclonidine = 24 Exclusions after randomization: none reported Number analyzed: Total: all laser treatments = 85; trabeculoplasty = 51 Per group: all laser treatments, brimonidine = 43, apraclonidine = 42; trabeculoplasty, brimonidine = 27, apraclonidine = 24 Unit of analysis (participants vs eyes): participant (1 eye per participant) Losses to follow‐up: none How was missing data handled?: N/A Reported power calculation: no Unusual study design (any issues with study design)?: none
Participants	Age (mean ± SD; years): (only available for all laser treatments): brimonidine = 70 ± 12.0, apraclonidine = 67.3 ± 13.7 Females: (only available for all laser treatments): brimonidine = 67%, apraclonidine = 45% Inclusion criteria: medically uncontrolled IOP, any type of glaucoma, initial or repeat ALTs 180° to any quadrant Exclusion criteria: chronic topical alpha‐2 agonist therapy, use of topical alpha‐2 agonist within the past 2 weeks, active ocular infection or inflammation, abnormality precluding reliable applanation tonometry, unable to stay for the 1‐hour follow‐up IOP check Equivalence of baseline characteristics: no, "No significant difference were found among treatment groups in terms of age, race, or baseline IOP…There was a statistically significant difference in the gender distribution between groups…" Also noted that uneven distribution of pseudoexfoliation pigmentary glaucoma/mixed glaucoma may affect post laser IOP spike numbers
Interventions	Intervention 1: 1 drop apraclonidine hydrochloride 0.5%, 10 min prior to laser surgery Intervention 2: 1 drop brimonidine tartrate 0.2%, 10 min prior to laser surgery Length of follow‐up: Planned: 1 hour Actual: 1 hour
Outcomes	Primary outcome: IOP Secondary outcomes: mean IOP change, IOP elevation ≥ 5 mmHg change from baseline Adverse events reported: yes, reported no systemic or localized ocular reactions and no other adverse effects Intervals at which outcomes assessed: baseline; 1 hour after surgery
Notes	Trial registration: not reported Funding sources: not reported Disclosures of interest: "The authors hold no proprietary interest in the drugs used in this study." Study period: January 1998 to May 1998 Reported subgroup analyses: yes, subgroups were different types of anterior segment laser procedures
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not reported.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Masking of participants and personnel (performance bias)	Unclear risk	No information on masking of participants and personnel reported.
Masking of outcome assessment (detection bias)	Low risk	IOP analysis performed by the same masked observer at 1 hour post laser, every effort was made to use the same tonometer as prior to surgery.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow‐up; all participants who were randomized completed all assessments. Exclusion criteria was for people who could stay for 1 hour post laser surgery, so there was no attrition.
Selective reporting (reporting bias)	Unclear risk	Unclear whether there was selective outcome reporting.
Other bias	Unclear risk	Funding sources not reported. Also, this study reported subgroup analysis for the ALT group but did not report baseline demographics by subgroup.